Galderma Agrees to Buy ZO Skin Health for $1.5 Billion in Cash
Galderma has agreed to buy 100% of ZO Skin Health for $1.5 billion, measured as enterprise value, and to pay in cash Press Release Hub.
Galderma is a Swiss skincare company and ZO Skin Health makes medical-grade skincare. On Oct. 13, early reports put the price at around $1.5 billion Reuters.
The formal news came on Oct. 14. It listed full ownership, enterprise value and cash payment. It was an agreement, not a finished deal.
The broader context here is what $1.5 billion means. Think of it like the sticker price on a house. Enterprise value is the business itself, before loans and cash are counted. What sellers finally get depends on cash, debt and unpaid bills at closing. The headline starts the story. Closing papers set the final cheque.
In my view, the headline alone can mislead. The key step is from enterprise value to final payment, at signing and at close. Net debt, deal fees and delayed payments can change the cash paid. Analysts will link the headline to cash paid.
Looking at what this means for funding, paying all cash for 100% is simple. No new shares. No share-swap ratio. No collar to value. The buyer would own all of it and keep full control from close. It would also put funding strain on its own cash and borrowing, not share it with sellers. Investors need not work out extra shares or a vote tied to a share price.
The broader question for borrowing is simple. Big cash deals test cash planning. Finance teams weigh cash on hand against new loans, debt coming due and lending limits. Rating and loan-cost effects depend less on strategy talk and more on debt after the deal and cash left after bills. Cash left, costs to get savings and spending to join systems will set how fast debt falls.
In my view, owning 100% also makes accounts simpler but leaves less room to share risk. It is like owning the whole house rather than sharing it. A full purchase lets Galderma add up results fully and run sales and supply directly. There would be no minority holder to cushion ups and downs or share costs. Results from ZO would go straight into group results.
The broader lesson for deal screening is to treat rumours and signed deals differently. Around $1.5 billion from sources and $1.5 billion in a signed deal mean different things for risk. One helps positioning. The other sets legal exposure.
Looking at what comes next, the time between agreement and close matters most. Contract terms, major-problem clauses, regulator approvals and final deadlines usually decide if headline terms hold. Until those steps are met or waived, $1.5 billion is a promised yardstick, not money moved.
